Featured Story

Pharma's budding opportunity

Why the industry is forming bonds with CBD

PM1906 WebLeadImage 295X269 1

No single molecule has likely ever generated as much buzz in the wellness market as CBD.Cannabidiol — commonly known as CBD — is one of the primary, non-psychoactive compounds found in the cannabis plant. A recent loosening of regulations for CBD has triggered an explosion of over-the-counter dietary supplements touting so many therapeutic uses for the molecule, it almost sounds magical.Not long ago, cannabis products were widely viewed as a threat to the pharma industry, partly because of the competition they could pose within key therapeutic areas such as pain management. But these days, the smoky cloud of suspicion around marijuana and its derivatives has begun to…

Full Story

Pharma Manufacturing Exclusives

Fundamentals

Valuable educational content — from tutorials to reference guides —  for all pharmaceutical manufacturing professionals.

Research Zone

A collection of news stories highlighting advances in medical science and pharmaceutical R&D.

Funny Pharm

Write a caption and win!

Aug15homepageBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • Modernizing manufacturing through a connected shop floor

    By Michael Jovanis, vice president, Vault Quality, Veeva Systems

    The shop floor is ripe for digital transformation. Manufacturing operations are still mostly paper-based, with aging systems also in use long past their shelf life. Adapting to new processes, manufacturing or training methods, or production requirements is difficult because processes are manual and…

    Full Story
  • A dose of Washington comes to CPhI in Chicago

    By Meagan Parrish, Senior Editor

    Sen. Jeff Flake (R-Arizona) During his keynote address to a packed auditorium inside CPhI North America in Chicago this April, it became clear that Sen. Jeff Flake (R-Arizona) is one of the last of a dying breed. While combative politics continue to create gridlock inside the nation’s capital,…

    Full Story
  • Joint ventures in pharma (and nature)

    By Karen Langhauser, Chief Content Director

    Often, symbiotic relationships come naturally. I recently learned (via Animal Planet at 1 a.m.) that coyotes and badgers are frequently seen hunting together. This struck me as bizarre, as the two animals are generally competing for the same meal.“Don’t be fooled,” said the narrator, “these…

    Full Story
  • Pharma's budding opportunity

    By Meagan Parrish, Senior Editor

    No single molecule has likely ever generated as much buzz in the wellness market as CBD.Cannabidiol — commonly known as CBD — is one of the primary, non-psychoactive compounds found in the cannabis plant. A recent loosening of regulations for CBD has triggered an explosion of over-the-counter…

    Full Story
  • Solid Dose: Under-hyped but not under-represented

    By Karen Langhauser, Chief Content Director

    Tablets may not be as glamorous or cutting-edge as emerging sectors of the biologics markets, but they have their upsides. Oral solid dose formulations are efficient and cost-effective to manufacture, shelf stable and easy to administer. Perhaps most importantly, they are understood and accepted by…

    Full Story
  • The future is transparent

    By Pierre-François Thaler Co-Founder and Co-CEO, EcoVadis

    It’s no doubt an interesting time for pharma. Competition is fierce in the tight race for new drug discovery. Many leading companies are merging and acquiring where they can to fill gaps in product portfolios and R&D and more importantly, gain access to new markets — especially the U.S.,…

    Full Story

Latest Products